Iovance Biotherapeutics (NASDAQ:IOVA) Upgraded to "Hold" at Truist Financial

2026-03-26 06:32:58 ET

Truist Financial upgraded shares of Iovance Biotherapeutics ( NASDAQ:IOVA – Free Report ) to a hold rating in a report issued on Wednesday, Zacks.com reports.

IOVA has been the topic of a number of other reports. The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Chardan Capital dropped their price objective on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Wall Street Zen upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Citizens Jmp raised Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 target price on the stock in a report on Tuesday, March 3rd. Finally, Barclays boosted their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.88.

View Our Latest Analysis on Iovance Biotherapeutics

Iovance Biotherapeutics Price Performance

Shares of IOVA opened at $3.75 on Wednesday. Iovance Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $5.63. The company has a 50 day simple moving average of $3.27 and a two-hundred day simple moving average of $2.66. The firm has a market cap of $1.54 billion, a P/E ratio of -3.35 and a beta of 0.69.

Iovance Biotherapeutics ( NASDAQ:IOVA – Get Free Report ) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million for the quarter, compared to analysts’ expectations of $81.61 million. On average, sell-side analysts anticipate that Iovance Biotherapeutics will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several institutional investors have recently modified their holdings of the stock. State Street Corp boosted its holdings in shares of Iovance Biotherapeutics by 51.5% in the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after purchasing an additional 6,851,486 shares during the period. Palo Alto Investors LP raised its holdings in Iovance Biotherapeutics by 122.1% during the 3rd quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after buying an additional 4,188,803 shares during the period. HRT Financial LP lifted its position in Iovance Biotherapeutics by 1,078.3% in the fourth quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock worth $11,891,000 after buying an additional 3,986,314 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after buying an additional 3,869,617 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after buying an additional 3,148,096 shares during the period. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Company Profile

( Get Free Report )

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.

Featured Stories

• Five stocks we like better than Iovance Biotherapeutics